

Doctor referral of overweight people to low energy treatment: the DROPLET trial



CrossMark [#]

Condition category

Nutritional, Metabolic, Endocrine

Date applied

28/04/2015

Date assigned

19/05/2015

Last edited

18/12/2019

Prospective/Retrospective

Prospectively registered

Overall trial status

Completed

Recruitment status

No longer recruiting

Publication status

Results

Plain English Summary

Background and study aims

Around 1 in 4 people in the UK are seriously overweight (obese). Being obese makes it more likely that a person will develop diabetes, heart disease and some types of cancer. Extra body weight also puts a strain on muscles and joints, making it difficult and sometimes painful to move around. Together, these factors increase the likelihood that people who are overweight will experience poor health and a reduced quality of life. At the moment, doctors and nurses in primary care support people to lose weight by referring patients to a commercial weight loss provider offering support in a group setting, such as Weight Watchers. But weight loss in a group setting does not suit everybody. Another alternative available is low-energy total diet replacement. Low-energy diets have been used to help people lose weight for many years and there are a number of companies who provide diet products together with individual advice and support. Low-energy total diet replacement programmes usually consist of a period where regular foods are replaced entirely by meal replacement products, providing around 800 kcal a day. The diet has all the vitamins and minerals that are essential for good health, but contains a lot less energy than most people eat on a regular weight loss diet. This means that these type of programmes usually lead to more rapid weight loss, especially in the early weeks. However, it is not known whether low-energy total diet replacement programmes are effective at helping people maintain weight loss a year or more later. The aim of this study, the DROPLET study, is to test whether GPs referring patients who are obese to a low-energy total diet replacement programme, can help people to lose more weight than a weight loss programme provided by the practice nurse.

Who can participate?

Adults diagnosed as obese.

What does the study involve?

Participants are randomly allocated into one of two groups. Those in group 1 (intervention group) are put on a low energy total diet replacement diet plan by their GP. Those in group 2 (control group) are given standard care for weight management by their GP. Participants visit their GP practice at the start of the study, and then again 4, 12, 26 and 52 weeks later to see a GP, nurse or a member of the research team for follow up. Participants also speak to the study team over the phone at 4, 8 and 12 weeks into the study. Blood samples are taken at the start of the study, and again after 1 year, to see if there is any change in blood markers, such as cholesterol and insulin. This is to assess participants' risk of developing heart disease or diabetes. Participants also complete questionnaires at the end of the trial.

What are the possible benefits and risks of participating?

Everyone who takes part in the trial should benefit as both groups will receive support to help them to lose weight.

Where is the study run from?

Oxfordshire Clinical Commissioning Group (UK)

When is the study starting and how long is it expected to run for?

January 2015 to January 2018

Who is funding the study?

Cambridge Weight Plan Ltd (UK)

Who is the main contact?

Dr N Astbury

nerys.astbury@phc.ox.ac.uk

Trial website

□

Contact information**Type**

Scientific

Primary contact

Dr Nerys Astbury

ORCID ID

□

Contact details

Nuffield Department of Primary Care Health Sciences
Radcliffe Primary Care
Woodstock Road
Oxford
OX2 6GG
United Kingdom
+44 (0)18656 17871
nerys.astbury@phc.ox.ac.uk [<mailto:nerys.astbury@phc.ox.ac.uk>]

Additional identifiers**EudraCT number****ClinicalTrials.gov number****Protocol/serial number**

SJ/DROPLET/0012

Study information**Scientific title**

A randomised controlled trial of a low energy diet treatment compared with usual care for weight management in primary care

Acronym

DROPLET

Study hypothesis

Hypothesis as of 15/12/2016:

A GP referral of obese adults to a low energy diet treatment results in greater weight loss after 12 months than usual care for weight management in primary care.

Original hypothesis:

Does a GP referral of obese adults to a low energy liquid diet treatment result in a larger reduced weight change after 52 weeks than usual care for weight management in primary care?

Ethics approval

South Central –Oxford B Research Ethics Committee, 16/06/2015, ref: 15/SC/0337

Study design

Open individually randomised two-arm parallel group study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type

Treatment

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet.

Condition

Obesity in adults

Intervention

Participants are allocated to one of two groups:

1. GP referral to a low energy total diet replacement programme
2. Standard care for weight management offered by primary care providers

Intervention type

Behavioural

Phase

Drug names

Primary outcome measure

Change in mean body weight from baseline to 12 months.

Secondary outcome measures

Secondary outcome measures as of 15/12/2016:

1. Change in mean weight between baseline, 3 and 6 months
2. Proportion of participants achieving 5 and 10% weight loss at 12 months
2. Change in mean fat mass between baseline and 12 months
3. Change in mean low-density lipoprotein (LDL) cholesterol between baseline and 12 months
4. Change in mean HbA1c between baseline and 12 months
5. Change in mean systolic and diastolic blood pressure between baseline and 12 months

Original secondary outcome measures:

1. Change in mean weight between baseline, 12 and 26 weeks.
2. Change in mean fat mass between baseline and 12, 26 and 52 weeks.
3. Change in mean low-density lipoprotein (LDL) cholesterol between baseline and 52 weeks
4. Change in mean HOMA IR (insulin resistance) between baseline and 52 weeks
5. Change in mean systolic and diastolic blood pressure between baseline and 12 weeks, 26 weeks and 52 weeks.
6. Change in the SF-12 physical functioning scale between baseline and 52 weeks

Overall trial start date

01/01/2015

Overall trial end date

01/01/2018

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Participant is willing and able to give informed consent for participation in the study
2. Male or female, 18 years and older.

3. Body Mass Index ≥ 30 kg/m²
4. Likely to benefit from weight loss in the GP's opinion

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

270

Participant exclusion criteria

Exclusion criteria as of 15/12/2016:

1. Unable to understand English
2. Currently or recently (within 3 months of study entry) attended a weight management programme, currently participating in another weight loss study
3. Had bariatric surgery, or scheduled to have bariatric surgery
4. Breastfeeding, pregnant or planning to become pregnant during the course of the study.
5. Receiving insulin therapy
6. Heart attack or stroke within the last 3 months,
7. Heart failure of grade II New York Heart Association and more severe,
8. Angina, arrhythmia including atrial fibrillation or prolonged QT syndrome.
9. Taking MAOI medication
10. Taking anticoagulant medication (e.g. warfarin)
11. Taking varenicline (smoking cessation medication)
12. Chronic renal failure of stage 4 or 5
13. Active liver disease except fatty liver or anyone with a past history of hepatoma or within 6 months of onset of acute hepatitis.
14. People having active treatment for cancer other than skin cancer treated with curative intent by local treatment only, or people taking hormonal or other long-term secondary prevention treatment after initial cancer treatment.
15. Active treatment or investigation for possible or confirmed gastric or duodenal ulcer. (Maintenance treatment with acid-suppression is not a contraindication.)
16. Porphyria
17. Scheduled for surgery within 1 year
18. Any member of household is already enrolled in the study
19. Unwilling to provide blood samples
20. Patients that the GP judges not able to meet the demands of either treatment programme or measurement schedule. This may include severe medical problems not listed above or severe psychiatric problems including substance misuse that make following the treatment programme or adhering to the protocol unlikely.

Original exclusion criteria:

1. Unable to understand English
2. Currently or recently (within 3 months of study entry) attended a weight management programme, currently participating in another weight loss study or ever had bariatric surgery.
3. Breastfeeding, pregnant or planning to become pregnant during the course of the study.
4. Receiving insulin therapy
5. Heart attack or stroke within the last 3 months, heart failure of grade II New York Heart Association and more severe, or prolonged QT syndrome.
6. MAOI medication
7. Chronic renal failure of stage 4 or 5
8. Active liver disease except fatty liver or anyone with a past history of hepatoma or within 6 months of onset of acute hepatitis.
9. People having active treatment for cancer other than skin cancer treated with curative intent by local treatment only, or people taking hormonal or other long-term secondary prevention treatment after initial cancer treatment.
10. Active treatment or investigation for possible or confirmed gastric or duodenal ulcer. Maintenance treatment with acid-suppression is not a contraindication.
11. Porphyria
12. Scheduled or on a waiting list for surgery within 1 year
13. Any member of household is already enrolled in the study
14. Unwilling to provide blood samples
15. Patients that the GP judges not able to meet the demands of either treatment programme or measurement schedule. This may include severe medical problems not listed above or severe psychiatric problems including substance misuse that make following the treatment programme or adhering to the protocol unlikely.

Recruitment start date

01/01/2016

Recruitment end date

28/07/2016

Locations**Countries of recruitment**

United Kingdom

Trial participating centre

Oxfordshire Clinical Commissioning Group
Jubilee House, John Smith Drive Oxford Business Park South
Oxford
OX4 2LH
United Kingdom

Sponsor information**Organisation**

University of Oxford

Sponsor details

Research Services
University of Oxford
Joint Research Office
Block 60
Churchill hospital
Oxford
OX3 7LE
United Kingdom

Sponsor type

University/education

Website

□

Funders**Funder type**

Industry

Funder name

Cambridge Weight Plan Ltd (UK)

Alternative name(s)**Funding Body Type****Funding Body Subtype****Location****Results and Publications****Publication and dissemination plan**

Planned publication in a high-impact peer reviewed journal in 2018.

IPD Sharing plan:

The current data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

31/12/2018

Participant level data

To be made available at a later date

Basic results (scientific)**Publication list**

1. 2017 protocol in <https://www.ncbi.nlm.nih.gov/pubmed/28780559> [<https://www.ncbi.nlm.nih.gov/pubmed/28780559>]
2. 2018 results in <https://www.ncbi.nlm.nih.gov/pubmed/30257983> [<https://www.ncbi.nlm.nih.gov/pubmed/30257983>]
3. 2019 results in: <https://www.ncbi.nlm.nih.gov/pubmed/30801983> [<https://www.ncbi.nlm.nih.gov/pubmed/30801983>] (added 18/12/2019)

Publication citations**Additional files****Editorial Notes**

18/12/2019: Publication reference added. 28/09/2018: Publication reference added 08/09/2017: Publication reference (protocol) added. 07/03/2017: The recruitment start date has been corrected from 01/06/2015 to 01/01/2016. 15/12/2016: The following changes have been made to the record: 1. The ethics approval has been added 2. The hypothesis, secondary outcomes and exclusion criteria have been updated 3. The recruitment end date has been updated from 01/06/2016 to 28/07/2016 4. The publication and dissemination plan and IPD sharing plan have been added